VCBeat Health Contact Us
Home Rona Therapeutics Announces Preclinical Data for RN026, a Potential Once-Yearly RNAi Therapy Targeting Lipoprotein(a)

Rona Therapeutics Announces Preclinical Data for RN026, a Potential Once-Yearly RNAi Therapy Targeting Lipoprotein(a)

May 31, 2025 09:52 CST Updated 09:52
Rona Therapeutics

Nucleic Acid Drug Developer

Rona Therapeutics recently announced the presentation of preclinical data for its proprietary innovative RNA interference therapy, RN026, at the National Lipid Association's 2025 Annual Scientific Sessions in the United States. Preclinical studies have shown,This therapy targets lipoprotein(a) (Lp(a)), an independent risk factor for cardiovascular diseases, achieving a 99% reduction in Lp(a) levels in non-human primate (NHP) studies and is expected to support an annual dosing regimen.。


图片


According to the press release from Rona Therapeutics, RN026, as a breakthrough therapy, has demonstrated significant potential in the field of cardiovascular diseases such as atherosclerotic cardiovascular disease (ASCVD), aortic valve stenosis, and peripheral artery disease. Its differentiated long-acting properties, potent Lp(a) inhibition capability, and excellent safety profile offer notable advantages. Approximately 10%-20% of the global population has elevated lipoprotein(a) levels, and RN026 is expected to bring new hope for the treatment of cardiovascular disease patients.

Core Highlights of This Announcement


1. Powerful and long-lasting, breakthrough efficacy


  • In transgenic mouse models, a single 2mg/kg subcutaneous injection can achieve:Serum Apolipoprotein Apo(a) Levels Decreased by 98%, with effects lasting at least 42 days;

  • In non-human primate (NHP) research,Serum Lp(a) Reduced by Up to 99%; 95% of Lp(a) inhibition was still maintained 98 days after administration, andThe effect of reducing serum Lp(a) levels by approximately 80% lasted until day 154, suggesting the potential for once-a-year dosing.。


2. Precise Targeted Design


  • Targeting multiple sites within and outside the KIV-2 CNV region for robust efficacy;

  • Greatly reduce the possibility of sequence-related off-target effects.


3. Dual Benefits


  • In NHP studies, a 25% reduction in low-density lipoprotein cholesterol (LDL-C) levels was observed;

  • No toxic reactions were observed in the repeated dosing test on SD rats.


References:
[1] Rona Therapeutics Presents Breakthrough Data on RN026, a Potential Long-Acting Innovative RNAi Therapy Targeting Lipoprotein(a), at the 2025 National Lipid Association (NLA) Scientific Sessions. From https://www.prnasia.com/story/491086-1.shtml

Disclaimer: This article is for information exchange purposes only. The views expressed in the article do not represent the position of WuXi AppTec, nor does WuXi AppTec support or oppose the views mentioned in the article. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Image